A Novel Insight into the Antidepressant Effect of Cannabidiol: Possible Involvement of the 5-HT1A, CB1, GPR55, and PPARγ Receptors

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2024 Dec 10

PMID 39657242

Authors

Yang Miao

Fei Zhao

Wei Guan

Affiliations

Soon will be listed here.

Abstract

Background: Depression is a prevalent and disabling disorder that poses serious problems in mental health care, and rapid antidepressants are novel treatments for this disorder. Cannabidiol (CBD), a nonintoxicating phytocannabinoid, is thought to have therapeutic potential due to its important neurological and anti-inflammatory properties. Despite major advances in pharmacotherapy in experimental animals, the exact mechanism of antidepressant-like effects remains to be elucidated.

Methods: In this paper, we review the current state of knowledge on the antidepressant properties of CBD in numerous experimental and clinical studies.

Results: Accumulating evidence suggests that CBD has antidepressant properties in humans and animals with few side effects, suggesting that CBD may be a potential antidepressant. Furthermore, we discuss that CBD may therefore provide a potential treatment to exert antidepressant-like effects through various molecular targets, reducing inflammation, and enhancing neurogenesis.

Conclusions: Taken together with the growing popularity of CBD as a medicine, these findings extend the limited knowledge on the antidepressant effects of CBD. This potentially opens up new therapeutic means for the patients with depression.

References

Mechoulam R, Parker L . The endocannabinoid system and the brain. Annu Rev Psychol. 2012; 64:21-47. DOI: 10.1146/annurev-psych-113011-143739. View

Sellers E, Schoedel K, Bartlett C, Romach M, Russo E, Stott C . A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clin Pharmacol Drug Dev. 2016; 2(3):285-94. DOI: 10.1002/cpdd.36. View

Desvergne B, Michalik L, Wahli W . Transcriptional regulation of metabolism. Physiol Rev. 2006; 86(2):465-514. DOI: 10.1152/physrev.00025.2005. View

Jeon L, Buettner C, Snyder A . Pathways from teacher depression and child-care quality to child behavioral problems. J Consult Clin Psychol. 2014; 82(2):225-35. DOI: 10.1037/a0035720. View

Balachandran P, ElSohly M, Hill K . Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. J Gen Intern Med. 2021; 36(7):2074-2084. PMC: 8298645. DOI: 10.1007/s11606-020-06504-8. View

Thase M, Schwartz T . Using mechanism of action to choose medications for treatment-resistant depression. J Clin Psychiatry. 2015; 76(9):e1147. DOI: 10.4088/JCP.14052wc1c. View

de Wit H, Bershad A . MDMA enhances pleasantness of affective touch. Neuropsychopharmacology. 2019; 45(1):217-239. PMC: 6879524. DOI: 10.1038/s41386-019-0473-x. View

Alves F, Crestani C, Gomes F, Guimaraes F, Correa F, Resstel L . Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res. 2010; 62(3):228-36. DOI: 10.1016/j.phrs.2010.05.003. View

Samara E, Bialer M, Mechoulam R . Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos. 1988; 16(3):469-72. View

10.

Babalonis S, Haney M, Malcolm R, Lofwall M, Votaw V, Sparenborg S . Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017; 172:9-13. PMC: 5361620. DOI: 10.1016/j.drugalcdep.2016.11.030. View

11.

Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb A, Hoffman A . Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017; 266:1-7. DOI: 10.1016/j.jconrel.2017.09.011. View

12.

Pisanti S, Malfitano A, Ciaglia E, Lamberti A, Ranieri R, Cuomo G . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041. View

13.

Britch S, Babalonis S, Walsh S . Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2020; 238(1):9-28. PMC: 7796924. DOI: 10.1007/s00213-020-05712-8. View

14.

Mlost J, Kedziora M, Starowicz K . Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels. Pharmaceuticals (Basel). 2021; 14(10). PMC: 8541018. DOI: 10.3390/ph14100964. View

15.

De Petrocellis L, Ligresti A, Moriello A, Allara M, Bisogno T, Petrosino S . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2010; 163(7):1479-94. PMC: 3165957. DOI: 10.1111/j.1476-5381.2010.01166.x. View

16.

Melas P, Scherma M, Fratta W, Cifani C, Fadda P . Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int J Mol Sci. 2021; 22(4). PMC: 7917759. DOI: 10.3390/ijms22041863. View

17.

Jesulola E, Micalos P, Baguley I . Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet?. Behav Brain Res. 2017; 341:79-90. DOI: 10.1016/j.bbr.2017.12.025. View

18.

Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb A, Deutsch L . PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. J Pharm Sci. 2017; 107(5):1423-1429. DOI: 10.1016/j.xphs.2017.12.020. View

19.

Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk E . Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005; 27(6):799-810. DOI: 10.1097/01.ftd.0000177223.19294.5c. View

20.

OSullivan S, Skov Jensen S, Nykjaer Nikolajsen G, Ziegler Bruun H, Bhuller R, Hoeng J . The therapeutic potential of purified cannabidiol. J Cannabis Res. 2023; 5(1):21. PMC: 10262148. DOI: 10.1186/s42238-023-00186-9. View